Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Diabetes Health Center

Font Size

FDA Panel Opposes New Type of Diabetes Drug

Experts Concered That Dapagliflozin May Be Linked to Liver Damage or Cancer
WebMD Health News
Reviewed by Laura J. Martin, MD

Editor's note: On Jan. 19, 2012, the pharmaceutical companies AstraZeneca and Bristol-Myers Squibb announced that the FDA rejected their approval request for dapagliflozin, calling for more research data on the drug’s benefits and risks. Both companies say they remain committed to developing the drug and will work with the FDA to determine the next steps.

July 19, 2011 -- In a 9-6 vote, an advisory panel said the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight.

Signals of possible liver damage and of breast and bladder cancer worried the experts.

The split vote, as well as panelist comments, makes it uncertain whether the FDA will approve the drug, jointly made by Bristol-Myers Squibb and AstraZeneca. The FDA will certainly ask the companies to gather more data on side effects; the key question is whether the agency will ask for this data before or after approval.

Dapagliflozin is the first in a new class of diabetes drugs. Normally, the kidney recycles sugar back into the body. But dapagliflozin inhibits a transporter molecule called SGLT-2. The result: Sugar passes out of the body in the urine, lowering blood sugar without affecting insulin levels.

Another result: Patients lose weight. In clinical trials, type 2 diabetes patients who took dapagliflozin for six months lost 1 to 5 pounds. In a special study to look at weight loss in people with diabetes, 30% of those who took dapagliflozin plus metformin lost 5% of their body weight.

A downside to the drug is that diabetes often damages the kidneys. Even moderate loss of kidney function makes dapagliflozin much less effective. The drug would be given only to patients with sufficient kidney function, but some panelists questioned the value of a proposed test to determine which patients could take dapagliflozin.

And the drug has side effects. All that sugar in the urine increases patients' risk of urinary tract and genital infections. There are other worries, too -- including dehydration and heat intolerance -- but members of the advisory committee were far less worried about these side effects than about the possible risk of cancer and liver toxicity.

Today on WebMD

Diabetic tools
Symptoms, diagnosis, treatment, and more.
woman flexing muscles
10 strength training exercises.
Blood sugar test
12 practical tips.
Tom Hanks
Stars living with type 1 or type 2.
kenneth fujioka, md
Can Vinegar Treat Diabetes
Middle aged person
jennie brand miller

Prediabetes How to Prevent Type 2 Diabetes
type 2 diabetes
food fitness planner